Five recent developments in aesthetic dermatology

Study results showing that incidence of late reactions to injections of Juvéderm Volbella in the tear trough area or lips were higher than expected was among recent developments in aesthetic dermatology reported on Healio.com.

Other developments included Allergan expanding its neurotoxin pipeline with Anterios acquisition, and findings that carboxymethylcellulose filler was effective in treating the lower face:

Incidence of late reactions to Juvéderm Volbella higher than expected

Patients in Israel who received injections of Juvéderm Volbella in the tear trough area or lips had a higher than expected incidence of late cutaneous reactions, according to study results.

Researchers examined the medical records of 400 patients (360 women; average age, 49.6 years) who were treated with Juvéderm Volbella (hyaluronic acid; HA-Vb) filler at four medical centers in Israel. Read more

Carboxymethylcellulose filler effective in treating lower face

Patients injected with cross-linked carboxymethylcellulose filler had significant improvement in rejuvenation of the lower face, according to recently published study results.

“Carboxymethylcellulose (CMC) is a biosynthetic substance used in food science as a viscosity modifier or thickener already present in some dermal fillers as carrier or filling,” researchers in Italy wrote. “Since 2012, CMC hydrogel cross-linked by 1,4-butanediol diglycidyl ether has been approved for tissue augmentation and wrinkles correction [in Italy].” Read more

Early treatment may prevent skin necrosis related to nose augmentation with hyaluronic acid

Augmentation of the nose and nasolabial fold with hyaluronic acid may lead to impending nasal skin necrosis, according to study results.

Researchers in China reviewed medical records from between 2008 and 2014 to identify 20 patients (age range, 21 to 52 years; 90% women) who experienced skin necrosis associated with nose and or nasolabial fold augmentation with only hyaluronic acid fillers. Read more

Allergan expands neurotoxin pipeline with Anterios acquisition

Allergan announced in a press release the acquisition of Anterios, a biopharmaceutical company developing a next generation neurotoxin delivery system and botulinum toxin-based prescription products.

Allergan agreed to an upfront payment of $90 million, and commercialization milestone payments related to NDS, Anterios’ proprietary platform delivery system that allows for targeted delivery of neurotoxins through the skin without an injection, according to the release. Read more

ASDS honors cosmetic, dermatologic surgeons with President's Award

Four members of the American Society for Dermatologic Surgery have received a President’s Award, for contributing to the society or medical specialty “in an extraordinary or unique way,” according to a press release.

Jean Carruthers

Outgoing ASDS President George J. Hruza, MD, MBA, presented the awards at the 2015 ASDS annual meeting to Alastair Carruthers, FRCPC, and Jean D. Carruthers, MD, of Vancouver, British Columbia; Mark D. Kaufmann, MD, of New York; and Susan H. Weinkle, MD, of Bradenton, Fla. Read more